Erdheim-Chester disease : from palliative care to targeted treatment by G. Graziani et al.
Minireview
Erdheim–Chester disease: from palliative care to targeted treatment
Giorgio Graziani, Manuel A. Podestà, David Cucchiari, Francesco Reggiani and Claudio Ponticelli
Nephrology and Dialysis Unit, Humanitas Clinical and Research Center, Rozzano, Milano, Italy
Correspondence and offprint requests to: Giorgio Graziani; E-mail: giorgio.graziani@humanitas.it
Abstract
Erdheim–Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis
with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to
30% of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis is
usually based on histological analysis of the pathologic tissue, which typically shows xanthogranu-
lomatous infiltrates of foamy CD68+/CD1a- histiocytes surrounded by fibrosis. A consistent per-
centage of patients affected by ECD develop renal failure and hypertension as a consequence of
renal artery stenosis and hydronephrosis. These conditions have been generally treated with the
placement of stents and nephrostomies that frequently led to disappointing outcomes. Before
the introduction of interferon-alpha (IFNα) treatment, the mortality rate was as high as 57% in the
long term. Recent studies have granted new insights into the pathogenesis of ECD, which seems to
bear a dual component of clonal and inflammatory disease. These advances led to use specific ther-
apies targeting either the oncogenes (BRAFV600E) or the effectors of the immune response impli-
cated in ECD (IL-1, TNFα). Drugs such as anakinra (recombinant human IL-1 receptor antagonist),
infliximab (monoclonal antibody against TNFα) and vemurafenib (inhibitor of mutant BRAF)
showed promising results in small single-centre series. Although larger trials will be needed to
address the impact of these drugs on ECD prognosis and to select the most effective treatment,
targeted therapies hold the premises to drastically change the outcome of this condition.
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Introduction
Erdheim–Chester disease (ECD) is a non-Langerhans histio-
cytosis that affects multiple organs and systems. Since the
first description by Erdheim and Chester in 1930, ∼450
cases have been reported in international literature [1, 2].
The pathological hallmark of the disease is represented by
xanthogranulomatous infiltrates of foamy CD68+/CD1a-
histiocytes surrounded by fibrosis [3] (Figure 1). The clinical
features are highly dependent on the degree and severity of
organ involvement, leading to a multifaceted presentation
and to a challenging diagnosis. The aetiology and patho-
genesis of this condition remain poorly understood and also
its classification as a tumoral or inflammatory disease is
controversial [2, 4]. However, recent advances have allowed
a better understanding of the pathogenesis of ECD and to
the development of promising therapeutic strategies.
Clinical features and diagnosis
ECD is a multifaceted disorder, with various possible com-
binations of symptoms, which depend on the distribution
and severity of organ involvement. Mean age at presenta-
tion is 55 years (range 16–80 years), and men are usually
affected more frequently than women [5]. Clinical fea-
tures usually include constitutional symptoms, such as
weight loss, fever, night sweats, muscle and joint pain,
weakness and fatigue. Long bone involvement is almost
universal, with bilateral symmetrical and diffuse osteo-
sclerosis of knees and ankles, which causes juxta-articular
pain in ∼50% of cases [3, 6]. Another peculiar sign of ECD
is the circumferential sheathing of the thoracic and ab-
dominal aorta, which is complete in a minority of cases,
giving the appearance of a ‘coated’ aorta at computed
tomography (CT). Heart involvement is frequent and re-
presents the leading cause of death. Cardiac symptoms
are mainly due to pericardial effusion, with a high risk of
cardiac tamponade. Myocardial infiltration may also cause
a pattern described as ‘pseudotumour’ in the right heart.
Myocardial infarction and valvular heart disease have also
been reported. Indeed, heart failure induced by progres-
sive myocardial fibrosis and/or pericardial effusion is the
major cause of mortality [7]. Involvement of the brain and
pituitary gland results in manifestations ranging from
diabetes insipidus to cerebellar or pyramidal syndromes
(ataxia, dysarthria and nistagmus), cognitive impairment
and cranial nerve paralysis. The retro-orbital soft tissue is
frequently invaded, leading to exophtalmus and vision im-
pairment. Infiltration of liver, lungs, spleen, thyroid, skin,
conjunctiva and false vocal cord may also occur [3, 8].
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Kidneys may be involved in up to 30% of cases, with hy-
podense fibrotic tissue deposition in the perirenal fat and
hilum. This fibrotic tissue usually encases both kidneys, con-
ferring them a ‘hairy’ appearance on CT scans [8]. The pro-
gressive infiltration of the hilum often leads to renal artery
compression, which is responsible for renovascular hyper-
tension, ischaemic injury and renal failure. In addition, the
long-standing compression of renal parenchyma may result
in renin-angiotensin-aldosterone system activation, leading
to renovascular hypertension, even in the absence of a sig-
nificant renal artery obstruction (Page kidney phenomenon)
[9]. In some cases, the fibrotic tissue deposition may also
cause extrinsic obstruction of the pelvis and the proximal
ureteral segments, inducing bilateral hydronephrosis and
post-renal kidney injury. Kidney involvement is rarely symp-
tomatic, but disease progression leads to end-stage renal
disease in a rather high percentage of cases [10, 11].
Histological analysis of the perirenal infiltrates is the
gold standard for the diagnosis. ECD needs to be distin-
guished from immune-mediated or secondary (radio-
induced) retroperitoneal fibrosis (RPF), a rare disease that
often causes hydronephrosis and urinary tract obstruction.
In ECD both the vena cava and pelvic ureters are usually
unaffected, while in RPF a more extensive involvement
may be demonstrated by imaging techniques. In addition,
histological analysis in RPF cases usually shows diffuse in-
flammatory infiltrates, typically with a central core of
CD20+ cells and a mantle of CD3+ cells, with plasma cells
positive for the IgG4 isotype [12].
Pathogenesis
ECD pathogenesis is still incompletely understood, with
contrasting evidence supporting the theory of either a re-
active or a malignant disorder. Assessment of clonality
using different strategies has been inconclusive, with
studies favouring either monoclonality or polyclonality
[13, 14].
Consistent efforts have been directed towards the eluci-
dation of the mechanism by which histiocytes are re-
cruited and accumulate in ECD. In a study by Stoppacciaro
et al. [15], the low expression of the proliferation marker
Ki-67 on ECD histiocytes, coupled with the absence of
mitosis, led the authors to conclude that the pathogenetic
contribution of proliferation to the disease is limited. The
same investigators also demonstrated a high expression
on foamy histiocytes of chemokine/chemokine receptor
pairs implied in monocyte migration activity (i.e. CCR1,
CCR2, CCR3, CCR5 and the ligands CCL4, CCL2, CCL20 and
CCL5). The interaction of these molecules may generate
an autocrine loop, leading to histiocytes recruitment and
accumulation. In addition, they described a prominent T-
helper lymphocyte infiltration with intense IFNγ staining
and the expression on histiocytes of IP-10, which is an
IFNγ-induced chemokine. These findings were consistent
with a Th1-oriented inflammatory response. Histiocyte-
secreted chemokines such as CCL5, IP-10, CCL19 and
CCL2 may be responsible for the recruitment of these lym-
phocytes, which in turn may determine histiocyte activa-
tion and chemokine production, in a self-renewing loop.
Aouba et al. [16] measured the serum levels of different
cytokines and the expression of IL-1α on the surface of
monocyte cell from two ECD patients. The authors found
that the levels of pyrogenic cytokines such as IL-6, TNFα
and IL-1β, as well as the expression of IL-1α on mono-
cytes, were significantly higher in these patients com-
pared with the controls. The authors also demonstrated
an abrupt decrease of IL-1α expression following the ad-
ministration of Anakinra, a recombinant non-glycosylated
form of human IL-1 receptor antagonist (IL-1Ra). This
study suggested a pivotal role for IL-1 cytokine family as a
main actor in ECD pathogenesis.
Other investigators advocated a central role of tumour
necrosis factor alpha (TNFα) in ECD patients. In addition to
increased levels of IL-1β, IL-6, CCL2 and CCL5, Dagna et al.
[17] also found high levels of plasma soluble TNF receptor I
(sTNFRI) and II (sTNFRII), which are considered as markers
of TNFα activity. This hypothesis was supported by the
decrease of these markers during anti-TNFα therapy with
infliximab.
Arnaud et al. [18] further elucidated the cytokine
pattern underlying ECD pathophysiology. In a large series
of 37 patients they demonstrated that a 5 cytokine signa-
ture (IFNα, IL-12, MCP-1, IL-4 and IL-7) could be used to
identify ECD patients.
Taken together, all these data seem to tip the scale
towards an inflammatory origin of the disease, specifically
a Th1-oriented disorder. Nevertheless, recent findings led
to disprove this one-sided view. Haroche et al. [19] re-
ported that in 13 of 24 ECD patients histiocytes harboured
an activating mutation of the proto-oncogene BRAF
(BRAFV600E), which is involved in the mitogen-activated
protein kinase (MAPK) pathway. Recent studies indicated
that the percentage of ECD patients carrying a BRAF mu-
tation might have been initially underestimated. Cangi
et al. [20] detected BRAFV600E exploiting an ultrasensitive
technique in all of their 18 patients, but they were able to
identify the mutation only in 12 patients when using con-
ventional techniques. The same mutation was also de-
tected on peripheral blood mononuclear cells from all of
the patients and in none of the serum from controls.
Other authors also described single cases of ECD with
somatic activating mutations of NRAS, a proto-oncogene
upstream of BRAF in the MAPK pathway [21, 22]. This
further emphasizes the relevance of activating mutations
in the pathogenesis of ECD.
Interestingly, activating mutations of the MAPK pathway
have been linked to oncogene-induced senescence, a
protective mechanism against neoplastic transformation
characterized by the expression of high levels of onco-
suppressor proteins (i.e. p16Ink4a), which can induce a
Fig. 1. Histological analysis of the perirenal fat in a patient with ECD,
showing fibromuscular and adipose tissue with infiltrates of foamy
histiocytes surrounded by fibrosis.
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senescence-associated secretory phenotype [23, 24]. This
inflammatory response is characterized by the expression
of cytokines/chemokines that resembles the cytokine
pattern of ECD histiocytes, and which could lead to the
recruitment of non-mutated histiocytes at the lesion
site [20]. This may represent the link between the two
pathogenetic hypotheses regarding ECD: an oncogenic
mutation responsible for a limited clonal proliferation that
leads to a senescence-associated secretory phenotype
and a Th1-oriented inflammatory response capable
of worsening the initial lesion (Figure 2). Further work
is needed to clarify the contribution of each of these
components to ECD pathogenesis.
Treatment
There is currently no consensus on the best treatment for
ECD. This is largely due to the lack of clinical trials, which
are difficult to be realized owing to the rarity of this condi-
tion. Before the introduction of targeted therapies, the
therapeutical approach to kidney involvement was mainly
based on palliative treatments such as renal artery or
ureteral stenting, the latter being often complicated
by bladder irritation, dislocation, infection and blockage
by encrustation.
Steroids were initially the most commonly employed
systemic therapy, along with other cytotoxic drugs. In a
series 17 of 59 patients presented with retroperitoneal
involvement that led to hydronephrosis and renal
impairment in less than a half of cases. However, the re-
ported mortality rate was 57%, with respiratory distress
and heart failure as the most common cause of death [3].
Cladribine, a purine analogue that causes monocyte and
T-lymphocyte depletion, obtained partial regression of
ocular or cerebral symptoms in few cases, but the evi-
dence supporting this therapy is anecdotal [25, 26], and
no data on the efficacy on kidney involvement are avail-
able (Table 1).
ECD prognosis improved after Braiteh et al. introduced
IFNα therapy in three patients with advanced systemic in-
volvement: in a subsequent survival analysis, treatment
with IFNα was an independent predictor of survival [27,
28]. Indeed, IFNα may activate CD40-ligand, a member of
the TNF superfamily which binds to CD40 on dendritic
cells. CD40-ligand accelerates the maturation of dendritic
Fig. 2. Hypothesis on the pathogenesis of ECD (see text for explanation). HBRAF: BRAFV600E mutated histiocytes; SASP: senescence-associated secretory
phenotype; H: wild-type histiocytes; Th: T-helper lymphocytes.
Table 1. Therapeutic approaches to ECD
Treatment Target
Author (first
reported) Year
Largest
series
Steroids Glucocorticoid
receptor
Veyssier-Belot
et al. [3]
1996 20 patients
Cladribine Adenosine
deaminase
Myra et al. [25] 2004 1 patient
IFNα/PEG-IFNα CD40L Braiteh et al. [27] 2005 46 patients
Anakinra IL-1 Aouba et al. [16] 2010 2 patients
Infliximab TNFα Dagna et al. [17] 2012 2 patients
Vemurafenib BRAFV600E Haroche et al. [34] 2013 3 patients
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cells and favours immune-mediated destruction of histio-
cytes. Moreover, IFNα not only exerts immunomodulatory
effects but can also inhibit the inflammatory response by
reducing lesional histiocyte recruitment. Single-centre ex-
periences provided proof of the efficacy of IFNα on renal
involvement [29]. Nevertheless, the beneficial effect of
IFNα therapy seems to depend on individual response and
on organs involved. Moreover, only high doses of the drug
could obtain a significant improvement of symptoms in
∼2/3 of patients, but half of them complained of severe
side effects [16].
In the last few years, new insights on ECD pathogenesis
led to test targeted therapies, which showed promising
results. Anakinra is a recombinant, non-glycosylated form
of human IL-1Ra which binds to IL-1 membrane receptor
and down-regulates the biologic activities of IL-1, includ-
ing inflammation [30]. This effect is somewhat similar to
that exerted by IFNα, which, in fact, increases the expres-
sion of IL-1Ra. Aouba et al. [16] first reported a significant
reduction of IL-1α (a form expressed at the monocytes
membrane surface after cell stimulation) following treat-
ment with Anakinra in two ECD patients. One of the pa-
tients presented with a history of retroperitoneal and
periureteral fibrosis associated to bilateral hydronephrosis,
which was unresponsive to corticosteroids and required bi-
lateral ureteral stenting. Another patient had right ureter-
al stenosis and periarterial lesions with renal artery
stenosis and renovascular hypertension, which were par-
tially responsive to IFNα. Both patients showed a good re-
sponse to the administration of 100 mg/day of anakinra,
with reversal of hydronephrosis and total/partial recovery
of renal function. Anakinra also showed relevant beneficial
effects in ECD patients with extensive skeletal lesions [31]
or with severe cardiac involvement [32]. In all cases the
treatment induced a reduction of inflammatory markers,
fever and other ECD-related systemic symptoms. In add-
ition, the treatment was generally well tolerated, especial-
ly when compared with the high occurrence of side
effects during IFNα therapy.
Infliximab, a chimeric monoclonal antibody against
TNFα, at a dose of 5 mg/kg every 6 weeks has been suc-
cessfully employed in two cases of ECD with cardiovascular
involvement [17]. This therapy induced a marked improve-
ment of symptoms and cardiac function, mainly due to
the reduction of pericardial effusion and infiltrating tissue.
TNFαwas recently linked to endothelial barrier disruption in
ECD patients, which was prevented in vitro by the adminis-
tration of infliximab: this may explain the marked activity of
the drug on cardiac involvement [33]. However, only one
patient from this study presented with bilateral renal artery
stenosis-induced renal failure, and the follow-up was too
short to show any difference in kidney infiltrates.
Finally, the inhibitor of mutant BRAF vemurafenib at a
dose of 1920 mg/day has shown dramatic efficacy in
three BRAFV600E mutated cases of ECD. The treatment had
a rapid effect on cardiovascular, skin and ocular involve-
ment. In one of the patients, vemurafenib induced a com-
plete resolution of hydronephrosis and pyelocaliceal
dilation, which allowed the removal of nephrostomies and
ureteral stents [34].
Although anecdotal, these reports may pave the way to
a therapy targeted to different pathogenic mechanisms.
This may lead to a deeper understanding of ECD patho-
genesis and may contribute to lower the mortality asso-
ciated to this systemic condition. Larger trials are required
to assess the efficacy of each treatment and determine
the best approach to ECD.
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